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Presently, we have a large number of botulinum neuro-
toxins (BoNTs) at our disposal, but in the western hemi-
sphere these are limited almost exclusively to the
botulinum toxin A preparations: Abo- (ABO), inco-
(INCO), and onabotulinumtoxinA (ONA). Because these
are biological preparations, they are never identical to each
other, but they are, at most, similar to each other. Their
efficacy has been well demonstrated in numerous studies
and is undebated [1]. Since their introduction, new batches
have repeatedly been made available, and the purity of
ABO and ONA has essentially been improved upon. INCO
is the most recent formulation and is free of complex
proteins.
The paper by Frevert [2] in this issue addresses the
question of comparability of the three medications, focus-
ing mainly on the differential potency between the prepa-
rations and on the immunogenicity between them, giving
special consideration to the complex neurotoxin accessory
proteins (NAPs). It must be emphasized that the author of
the publication and the manufacturer of INCO view the
lack of these complex proteins as a major distinguishing
factor and in fact an advantage to their preparation.
The author addresses the topic of complexing proteins in
his abstract. Complexing proteins are not covalently bound
to the core neurotoxin itself, but are considered a part of the
active pharmacological ingredient. Furthermore, after in-
jection of BoNT, complexing proteins are shortly separated
from the neurotoxin due to a change in pH and other local
environmental factors, thus antibodies against complexing
proteins should not inhibit neurotoxin activity. The author
further describes differences between the three different
products related to their immunogenicity. Until now, there
has been no clinical evidence showing significant differ-
ences in immunogenicity between ABO, INCO, and ONA
[3] Furthermore, differences in assay sensitivity may lead
to differences of measured immunogenicity rates, thus no
direct comparison can be made today. Further studies en-
compassing long-term treatment are needed to assess dif-
ferences of immunogenicity amongst BoNT products.
Frevert raises many important considerations relevant to
BoNT therapy, although matters of potency require careful
interpretation. For example, Frevert states that one study
found equivalent potency across ONA and INCO [4], in an
assay that in fact was developed by Dr. Frevert and is used
by the company. However, the author fails to consider
contrasting results by Hunt who established potency dif-
ferences between the two products using two independent
assays—an LD50 and also a SNAP-25 cleavage [5, 6]. The
different results across these studies indicate underlying
differences between products that are evident under some
testing conditions but not others. A simple comparison of
the potencies of the preparations based merely on different
bioassays must be evaluated critically so as to avoid false
interpretations and the consequent negative effects on pa-
tients. If such differential potencies are described, the
regulatory requirements would have to be considered, as
would any peculiarities of the individual methods.
In several places, the author claims that studies show
‘‘clinical equipotency’’ of ONA and INCO at a 1:1 dose
ratio. This needs to be viewed in the light of several fac-
tors: (1) worldwide labeling clearly states that the units of
one toxin are not interchangeable with another; (2) non-
inferiority trial designs, as opposed to equivalence trial
designs, do not establish biologic equivalency for efficacy
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and safety [7, 8]; and (3) product response profiling needs
to be assessed at multiple doses and time points. For in-
stance, a randomized equivalence study established that 30
units of INCO was as effective as 20 units of ONA for
glabellar lines at the primary time point, but not at later
time points due to a trend toward higher response rates with
ONA [9]. Therefore, the dose-response profiles, and con-
sequently the products, are not equivalent. In clinical
practice, based on the registration trials [7, 8], a 1:1 ratio
was assumed for blepharospasm and cervical dystonia,
which does not establish scientific proof for equipotency.
To date, we do not have a defined ratio for comparing ABO
with INCO or ONA. Possibly, we have to define different
ratios for different indications and doses.
The active pharmaceutical ingredients of ONA and
ABO comprise BoNT, along with NAPs, which together
make up the neurotoxin complex, whereas INCO includes
only the neurotoxin protein. Based on pre-clinical and
in vitro data, the author concludes that the NAPs confer an
increased risk of immunogenicity and neutralizing anti-
bodies. This repeated conclusion is an over-interpretation
of pre-clinical and in vitro results without recognizing
clinical data. The conclusion that NAPs increase the risk of
neutralizing antibody formation is particularly conspicuous
in the abstract, where it is presented as a well-supported
fact without any caveat or critique. In fact, all three
products are associated with very low rates of neutralizing
antibodies and antibody-induced non-response in clinical
studies and practice, inasmuch as the ‘protein burden’ can
be taken as low-leveled for all three preparations [10]. At
the moment we do not know whether INCO is free of the
risk of reducing antibodies. This statement would have to
be confirmed in relevant studies. There is no clinical evi-
dence that NAPs are clinically relevant for inducing, acti-
vating, or increasing immunogenicity against BoNT. All
evidence to date is pre-clinical (in vitro and bio assay
in vivo in animals) [3].
The author writes that proteins protect the neurotoxin
from acidic and proteolytic degradation in the digestive
tract, and, in addition, they aid in stabilizing the neurotoxin
from changes in temperature [11].
BoNT-A can be considered as an excellent therapy for
dystonia and spasticity, with considerable advantages for
our patients. For a good number of years we have had two
different high-quality BoNT-A preparations available on
the market, and the introduction of INCO meant significant
progress [12]. These medications are biological prepara-
tions. Thus, they perform their service per definition in a
unique fashion, and are not easily exchangeable with each
other. Any comparisons of such substances require a high
degree of objectivity.
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